A novel combination of plumbagin and paclitaxel for the treatment of renal cell carcinoma

Grishma Saheba

Abstract


Paclitaxel is known chemotherapeutic that up-regulates NF-ĸB activation promoting chemoresistance. In this report the study focuses on whether plumbagin, a quinonoid, can sufficiently down-regulate the NF-ĸB activation and sensitize RCC cells to paclitaxel. It was found that Plumbagin possesses chemotherapeutical properties and does indeed down regulate NF-ĸB pathway modulated gene products. There was a strong synergy observed between plumbagin and paclitaxel. Overall, a novel combination of plumbagin and paclitaxel appear to have tremendous potential for the treatment of renal cell carcinoma.

Full Text:

PDF


© University of Toronto Journal of Undergraduate Life Sciences.